Hanmi Triple Agonist Obesity Drug Begins First Patient Dosing in US Phase 2 Trial
by Park Jeongyeon
Published 02 Feb.2026 15:15(KST)
Expansion of Indications to Diabetes Also Underway
Hanmi Pharmaceutical's next-generation triple agonist for obesity treatment, 'HM15275 (LA-GLP/GIP/GCG),' has begun patient dosing after entering Phase 2 clinical trials in the United States.
On February 2, Hanmi Pharmaceutical announced that it had completed dosing the first patient in the Phase 2 clinical trial approximately three months after receiving Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). The Phase 2 trial is expected to be completed in the first half of 2027. The company plans to accelerate development with the goal of commercializing the drug by 2030.
This Phase 2 clinical trial will focus on evaluating weight loss effects and changes in lean body mass in patients with obesity and severe obesity through long-term administration over 36 weeks.
HM15275 is a triple agonist that simultaneously stimulates the glucagon-like peptide (GLP)-1, gastric inhibitory polypeptide (GIP), and glucagon (GCG) receptors. The goal is to achieve greater weight loss compared to existing GLP-1 class drugs while minimizing muscle loss. Hanmi Pharmaceutical is targeting a weight reduction effect of more than 25% of body weight.
Currently available GLP-1-based obesity treatments, such as Wegovy (active ingredient: semaglutide) and Mounjaro (active ingredient: tirzepatide), have demonstrated weight loss effects of about 15–20% in clinical trials. However, they are considered limited because they have not achieved the 25–30% weight loss regarded as comparable to metabolic bariatric surgery.
Hanmi Pharmaceutical also plans to expand the indications for HM15275 to include diabetes treatment. In January of this year, the company received FDA approval for a Phase 2 IND to evaluate blood glucose control in diabetic patients and plans to initiate the clinical trial in the first half of this year.